We investigate patterns in common ownership networks between firms that are active in the US pharmaceutical industry for the period 2004-2014. Our main findings are that "brand firms" - i.e. firms that have R&D capabilities and launch new drugs - exhibit relatively dense common ownership...

Collaboration among various organizations is important for the sustainable creation of new innovative drugs. Previously, drug discovery was dominated by large pharmaceutical companies; however, various new players are now actively involved in this endeavor. Nevertheless, the factors affecting...